Gilead Total Debt To Capitalization from 2010 to 2024

GILD Stock  USD 73.01  0.60  0.83%   
Gilead Sciences' Total Debt To Capitalization is increasing over the years with slightly volatile fluctuation. Overall, Total Debt To Capitalization is expected to go to 0.55 this year. During the period from 2010 to 2024 Gilead Sciences Total Debt To Capitalization annual values regression line had geometric mean of  0.45 and mean square error of  0.01. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.52344143
Current Value
0.55
Quarterly Volatility
0.14575904
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead main balance sheet or income statement drivers, such as Interest Expense of 534.5 M, Total Revenue of 28.5 B or Gross Profit of 28.5 B, as well as many exotic indicators such as Short Term Coverage Ratios of 4.23, Price Earnings Ratio of 20.47 or Price To Sales Ratio of 3.54. Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.
  
This module can also supplement Gilead Sciences' financial leverage analysis and stock options assessment as well as various Gilead Sciences Technical models . Check out the analysis of Gilead Sciences Correlation against competitors.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Latest Gilead Sciences' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Gilead Sciences over the last few years. It is Gilead Sciences' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gilead Sciences' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

Gilead Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.49
Geometric Mean0.45
Coefficient Of Variation29.78
Mean Deviation0.1
Median0.53
Standard Deviation0.15
Sample Variance0.02
Range0.5601
R-Value0.61
Mean Square Error0.01
R-Squared0.37
Significance0.02
Slope0.02
Total Sum of Squares0.30

Gilead Total Debt To Capitalization History

2024 0.55
2022 0.54
2020 0.63
2019 0.52
2017 0.62
2016 0.56

About Gilead Sciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Gilead Sciences income statement, its balance sheet, and the statement of cash flows. Gilead Sciences investors use historical funamental indicators, such as Gilead Sciences's Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may use each financial statement separately, they are all related. The changes in Gilead Sciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Gilead Sciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Gilead Sciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Total Debt To Capitalization 0.52  0.55 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out the analysis of Gilead Sciences Correlation against competitors.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Transaction History
View history of all your transactions and understand their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.